Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

November 30, 2012

Conditions
Graves' Disease
Interventions
DRUG

Dexamethasone

The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.

Trial Locations (1)

210006

Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Xiao-Ming Mao

OTHER

NCT01534169 - Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients | Biotech Hunter | Biotech Hunter